The Relationship between Third-generation TSH Receptor Antibody Positivity and Cumulative Methimazole Dose Used until Remission in Graves' Disease | Journal of College of Physicians and Surgeons--Pakistan : JCPSP 2021

Author(s)

Serhat Ozçelik Department of Endocrinology and Metabolic Diseases, University of Health Sciences, Kartal Dr. Lütfi K1rdar City Hospital,Turkey

Mehmet Celik Department of Endocrinology and Metabolic Diseases, Faculty of Medicine, Trakya University Edirne,Turkey

Aski Vural Department of Internal Medicine, Ad1yaman Training and Research Hospital,Turkey

Bunyamin Aydin Department of Endocrinology and Metabolic Diseases, Ad1yaman Training and Research Hospital,Turkey

Hulya Gozu Marmara University Training and Research Hospital, Department of Endocrinology and Metabolism,Istanbul,Turkey

Abstract

Objective: To determine the relationship between the positivity of third-generation TSH receptor antibody (TRAb) at the time of diagnosis and the cumulative methimazole dose used until remission in patients with Graves disease. Study Design: Cross-sectional, descriptive study. Place and Duration of Study: Department of Endocrinology and Metabolic Diseases, University of Health Sciences, Kartal Dr. Lüt K1rdar City Hospital, Turkey from 2016 to 2018. Methodology: Newly diagnosed Graves' patients were included in the study. The patients were divided into two groups according to whether they entered remission (n: 21) or not (n: 20), in the 18th month of methimazole treatment. In addition, the patients were further divided into two categories, according to TRAb status at the time of diagnosis as negative (n: 17) or positive (n: 24). The TRAb positivity and the cumulative methimazole dose they used until the month of remission were compared in these groups. Results: The mean time to reach remission in 41 patients was 20.5 ± 3.1 months. TSH receptor antibody positivity rate was 58.5%. When the TRAb positivity of the groups was compared according to the state of having remission in the 18th month of the treatment, the positivity rate in the non-remission group was statistically signi cantly higher (p = 0.023T)h.e time to go into remission was longer and the cumulative methimazole dose requirement was higher in the TRAb positive group (p <0.001). Conclusion: Graves disease patients with positive third-generation TRAb were found to have a lower rate of remission in the 18month period compared to negative patients.

Publication Details

Page(s) 517-522

DOI DOI not available

Published Journal: Journal of College of Physicians and Surgeons--Pakistan : JCPSP, Volume: 31, Issue: 5, Year: 2021

Keywords

methimazole Cumulative Graves disease TSH receptor antibody

References

References are not available for this document.

Citations

Citations are not available for this document.